La Jolla Pharmaceutical (LJPC) Reports Q2 Loss of $0.70/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to La Jolla Pharmaceutical (LJPC) Reports Q2 Loss of $0.70/Share
August 7, 2015 8:00 AM EDT
SAN DIEGO--(BUSINESS WIRE)--
La
Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La
Jolla), a leader in the development of innovative therapies intended to
significantly improve outcomes in patients suffering from
life-threatening diseases, today reported second quarter 2015 financial
results and highlighted recent corporate progress.
Recent Corporate Progress
La Jolla initiated its ATHOS (Angiotensin
II for the...
More
August 5, 2015 8:01 AM EDT
SAN DIEGO--(BUSINESS WIRE)--
La
Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La
Jolla), a leader in the development of innovative therapies intended to
significantly improve outcomes in patients suffering from
life-threatening diseases, today announced that it has signed two
exclusive worldwide license agreements for the intellectual property
rights covering La Jollas next-generation gentamicin... More
